Compare Invesco DB Agriculture Fund (DBA) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco DB Agriculture Fund vs TransMedics Group Inc — how do they compare? Invesco DB Agriculture Fund trades at $28.43 (market cap $1.32B), while TransMedics Group Inc trades at $78.24 (market cap $2.74B). The key difference: TransMedics Group Inc is far larger — about 2.1× Invesco DB Agriculture Fund's market cap, and Invesco DB Agriculture Fund is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Invesco DB Agriculture Fund for 24 Days and TransMedics Group Inc for 24 Days on average.
| DBA | TMDX | |
|---|---|---|
Market Cap | $1.32B | $2.74B |
Volume | 771,657 | 949,331 |
52-Week High | $29.49 | $150.42 |
52-Week Low | $25.44 | $61.99 |
Typical Hold Time | 24 Days | 24 Days |
Sector | — | Health |
Enterprise Value | — | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DBA (Invesco DB Agriculture Fund ETF) trades at $28.42, down 0.25% on the day, with a bearish technical signal from moving averages but neutral oscillators. The fund has returned 12.4% year-to-date, closely tracking the S&P 500, supported by agricultural commodity strength from weather risks and geopolitical tensions. Recent news highlights DBA's consolidation near all-time highs with a 3.25% yield, though it faces a high expense ratio of 0.85%.
Outlook remains mixed with bullish agricultural trends from El Niño and demand catalysts balanced by sector volatility and expense concerns. Key risks include commodity price swings and geopolitical developments, while institutional sentiment leans neutral with a Hold rating from analysts citing momentum versus cost trade-offs.
TransMedics Group (TMDX) trades at $80.69, down 0.47% on the day, amid a bearish technical signal and mixed earnings performance. The company reported strong revenue growth to $605.49M in 2025 with a net income margin of 22.69%, but recent quarters have seen earnings misses. Analyst sentiment remains positive with a consensus price target of $99.75 and a 69% buy rating, though news flow includes investigations into fiduciary duties.
The outlook balances robust fundamentals against near-term headwinds. Upside potential exists from the high analyst target and strong profitability metrics like a 36.28% ROE, but risks include earnings volatility, margin pressure, and ongoing legal scrutiny. The stock's current valuation at a P/E of 20.47 offers a reasonable entry if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Invesco DB Agriculture Fund
The index, which is comprised of one or more underlying commodities ("index commodities"), is intended to reflect the agricultural sector. The fund pursues its investment objective by investing in a portfolio of exchange-traded futures.
Read more on DBA →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
